Nursing Elites

1. A patient has been using Viagra on an intermittent basis for several years. However, he has cited delays in the onset and peak of action as the occasional source of frustration. What PDE5 inhibitor may be of particular benefit to this patient's needs?

• A. Avanafil (Stendra)
• B. Tadalafil (Cialis)
• C. Vardenafil (Levitra)
• D. Alprostadil (Caverject)

Correct answer: A

Rationale: The correct answer is Avanafil (Stendra). Avanafil has a rapid onset of action compared to other PDE5 inhibitors, making it suitable for patients experiencing delays in onset and peak of action with other medications like Viagra. Tadalafil (Cialis), Vardenafil (Levitra), and Alprostadil (Caverject) do not offer the same rapid onset of action as Avanafil, making them less suitable for addressing the specific needs of this patient.

2. Which of the following is a factor that leads to increased risk for dehydration in the elderly?

• A. More insensible losses
• B. Increase in muscle mass
• C. Decline in kidney function
• D. Decrease in fat

Correct answer: C

Rationale: The correct answer is C: Decline in kidney function. As people age, their kidneys may not work as effectively in conserving water and concentrating urine, leading to a higher risk of dehydration. Choice A is incorrect because more insensible losses do not directly relate to an increased risk of dehydration in the elderly. Choice B, an increase in muscle mass, is not a factor that leads to dehydration. Choice D, a decrease in fat, is also not a direct factor contributing to dehydration in the elderly.

3. A patient is taking testosterone for hypogonadism. What adverse effect should the nurse monitor for during this therapy?

• A. Increased risk of liver dysfunction
• B. Increased risk of cardiovascular events
• C. Increased risk of prostate cancer
• D. Increased risk of bone fractures

Correct answer: B

Rationale: The correct adverse effect to monitor for when a patient is taking testosterone for hypogonadism is an increased risk of cardiovascular events. Testosterone therapy has been associated with an elevated risk of cardiovascular events such as heart attack and stroke, especially in older patients. Monitoring cardiovascular health is crucial during testosterone therapy. The other choices are incorrect because testosterone therapy is not primarily linked to liver dysfunction (choice A), prostate cancer (choice C), or bone fractures (choice D).

4. A patient with a history of osteoporosis is prescribed raloxifene (Evista). What is the primary therapeutic effect of this medication?

• A. It stimulates the formation of new bone.
• B. It decreases bone resorption and increases bone density.
• C. It increases calcium absorption in the intestines.
• D. It increases the excretion of calcium through the kidneys.

Correct answer: B

Rationale: The correct answer is B. Raloxifene, such as Evista, works by decreasing bone resorption and increasing bone density. This medication is beneficial in the prevention and treatment of osteoporosis by slowing down the breakdown of bone tissue, thereby reducing the risk of fractures. Choices A, C, and D are incorrect because raloxifene does not directly stimulate the formation of new bone, increase calcium absorption in the intestines, or increase the excretion of calcium through the kidneys.

5. A male patient is receiving testosterone therapy for hypogonadism. What adverse effect should the nurse be most concerned about?

• A. Increased risk of breast cancer
• B. Increased risk of liver dysfunction
• C. Increased risk of cardiovascular events
• D. Increased risk of prostate cancer

Correct answer: C

Rationale: The correct answer is C: Increased risk of cardiovascular events. Cardiovascular events such as stroke and myocardial infarction are the most concerning adverse effects of testosterone therapy, especially in older patients. Choice A, increased risk of breast cancer, is not a common adverse effect of testosterone therapy in males. Choice B, increased risk of liver dysfunction, is a potential adverse effect but is not the most concerning. Choice D, increased risk of prostate cancer, is a consideration in patients with a history of prostate cancer or those with prostate carcinoma, not typically in patients receiving testosterone therapy for hypogonadism.

Similar Questions